Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Polaris Capital Management LLC

Polaris Capital Management LLC decreased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 62.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,100 shares of the company’s stock after selling 22,000 shares during the period. Polaris Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $349,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of AMPH. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Amphastar Pharmaceuticals by 5.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock valued at $217,000 after purchasing an additional 465 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock worth $652,000 after purchasing an additional 613 shares during the last quarter. Global Retirement Partners LLC grew its stake in Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after buying an additional 703 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Amphastar Pharmaceuticals by 356.0% in the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after purchasing an additional 737 shares during the period. Finally, GAMMA Investing LLC increased its position in Amphastar Pharmaceuticals by 62.2% in the 2nd quarter. GAMMA Investing LLC now owns 2,162 shares of the company’s stock worth $50,000 after buying an additional 829 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $29.40 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21. The firm has a 50-day moving average of $26.54 and a 200-day moving average of $25.87. The company has a market cap of $1.35 billion, a PE ratio of 13.01, a price-to-earnings-growth ratio of 4.91 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $39.01.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. As a group, equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on AMPH. Zacks Research cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Barclays started coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price objective on the stock. Needham & Company LLC lowered their target price on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $31.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 9,787 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total transaction of $256,419.40. Following the completion of the transaction, the executive vice president owned 138,043 shares of the company’s stock, valued at approximately $3,616,726.60. This trade represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Floyd F. Petersen sold 16,679 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total value of $441,826.71. Following the transaction, the director directly owned 75,531 shares of the company’s stock, valued at approximately $2,000,816.19. This represents a 18.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 35,308 shares of company stock worth $931,637 over the last 90 days. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.